At the core of this gathering was the SCAI’s mission to foster scientific innovation, policy advancement, and professional growth within cardiovascular intervention. With cardiovascular disease claiming close to one million lives annually across North America alone—surpassing fatalities caused by respiratory diseases and cancers combined—the urgency to deepen understanding and refine intervention techniques in this arena cannot be overstated. The multidisciplinary sessions spanned coronary artery disease, structural heart disease, peripheral artery disease, pharmacotherapy, and even considerations emerging from the COVID-19 pandemic’s cardiovascular impacts.

A prominent focus lay on coronary heart disease, the most prevalent form of cardiovascular illness worldwide. Experts presented new clinical trials and evidence aimed at refining the acute management of myocardial infarctions and cardiogenic shock. Notably, the SELUTION DeNovo Trial unveiled data on Sirolimus Eluting Balloons for acute coronary syndrome patients, potentially redefining percutaneous intervention methods with drug-eluting balloon technologies targeted at reducing restenosis and revascularization rates. Additional presentations delved into strategies for reducing mortality in cardiogenic shock and identifying clinically important subgroups post-STEMI utilizing data from large-scale registries and randomized trials.

Structural heart disease, affecting millions globally, formed another critical topic area. The Scientific Sessions highlighted technological advancements such as transcatheter mitral valve replacement with devices like the AltaValve—a transcatheter prosthetic featuring atrial fixation designed to improve procedural feasibility and one-year patient outcomes in mitral valve interventions. These innovations could revolutionize therapy by making structural interventions less invasive, reducing surgical risks, and expanding treatment candidacy among high-risk patients previously limited by anatomy or comorbidity burdens.

Pharmacotherapy research underscored its integral role in cardiovascular treatment regimens. Presenters discussed the unaddressed residual risk in lipid management elucidated by elevated Lipoprotein(a) levels, based on rigorous analysis from NIH randomized trials. Such insights drive the refinement of lipid-lowering protocols beyond conventional LDL cholesterol targets. Additional data on the impact of SGLT2 inhibitors post-percutaneous coronary intervention (PCI) in patients exhibiting type 2 diabetes mellitus and coronary artery disease provided compelling evidence for integrating these agents into comprehensive secondary prevention strategies.

Peripheral artery disease (PAD) emerged as a critical area given its prevalence—affecting an estimated 10 million adults over 40 in the United States alone—and its status as the leading cause of limb amputation worldwide. The conference showcased novel interventional approaches like transcatheter arterialization of deep veins for chronic limb-threatening ischemia (CLTI), as demonstrated in the PROMISE III study, which assessed quality of life and clinical outcomes at six months post-procedure. Comparisons between radial-to-peripheral versus traditional femoral access for PAD revascularization in the CARPOOL study further revealed procedural nuances impacting patient recovery and complication rates.

The lingering cardiovascular ramifications of the COVID-19 pandemic were addressed with emerging registry data providing longitudinal insights into one-year outcomes for patients experiencing ST-segment elevation myocardial infarction (STEMI) concurrent with COVID-19 infection. Such studies contribute to clarifying whether the pandemic catalyzed increased myocardial infarction rates through viral pathology or indirect effects, shaping future post-discharge risk stratification and secondary prevention algorithms.

Beyond clinical trials and device trials, the summit fostered vital cross-border collaboration, emphasizing the integration of multidisciplinary professional knowledge to elevate care standards globally. Leaders from both SCAI and CAIC-ACCI accentuated the importance of combining rigorous education, comprehensive research, and shared innovation to empower cardiology professionals in making evidence-based, patient-centered decisions, ultimately translating into improved clinical outcomes.

This edition of the Scientific Sessions solidified SCAI’s role at the vanguard of interventional cardiology advancement, delivering an expansive program rich with live case demonstrations, featured clinical research, and novel guideline presentations. The seamless cooperation between American and Canadian interventional communities exemplifies international synergy, strengthening the collective capacity to tackle cardiovascular health’s evolving challenges.

For participants at all career stages—from fellows to seasoned experts—the conference provided unparalleled opportunities for professional development through leadership sessions, networking, and exposure to translational science bridging bench discovery with bedside application. As the prevalence of cardiovascular diseases continues to impose profound individual and societal burdens, the acceleration of innovation and knowledge dissemination remains imperative.

In sum, the SCAI Scientific Sessions 2026 & CAIC-ACCI Summit represented more than an academic convention; it symbolized the unrelenting pursuit of excellence in cardiovascular intervention. By elucidating novel therapeutics, optimizing procedural strategies, and exploring emerging disease intersections such as COVID-19, the summit accentuated the dynamic evolution within interventional cardiology poised to improve patient lives worldwide.

Subject of Research: Interventional cardiology advancements, clinical outcomes in coronary and structural heart diseases, peripheral artery disease treatment, pharmacotherapy in cardiovascular disease, and cardiovascular impacts of COVID-19.

Article Title: Breakthroughs and Innovations in Interventional Cardiology Spotlighted at SCAI Scientific Sessions 2026 & CAIC-ACCI Summit

News Publication Date: April 8, 2026

Web References:

• https://www.scai.org/education-and-events/events-schedule/scai-2026-scientific-sessions-caic-acci-summit
• https://www.cdc.gov/heart-disease/data-research/facts-stats/index.html
• https://caic-acci.org/

Image Credits: Society for Cardiovascular Angiography & Interventions and Canadian Association of Interventional Cardiology

Keywords: Interventional Cardiovascular Medicine, Coronary Heart Disease, Structural Heart Disease, Peripheral Artery Disease, Pharmacotherapy, COVID-19 Cardiovascular Impact, Transcatheter Mitral Valve Replacement, Sirolimus Eluting Balloons, SGLT2 Inhibitors, Cardiogenic Shock, Late-Breaking Clinical Trials, Cardiovascular Innovation

Every year, tens of thousands of individuals worldwide endure the life-threatening trauma of a heart attack, medically known as an acute myocardial infarction. The primary pathophysiology involves a sudden and complete obstruction of a coronary artery, often due to a thrombus formation superimposed on a ruptured atherosclerotic plaque. This occlusion precipitates ischemia and potential necrosis of downstream myocardium if not promptly alleviated. The standard of care demands rapid percutaneous coronary intervention (PCI) to reopen the culprit vessel, typically via angioplasty and stent placement, thereby restoring myocardial perfusion and limiting infarct size.

However, during such interventions, it is not uncommon for cardiologists to detect additional coronary arteries exhibiting significant stenoses. The clinical dilemma arises from whether these non-culprit lesions should receive immediate attention through concurrent stenting or whether treatment can be safely postponed. Historically, guidelines have generally favored comprehensive immediate revascularization, predicated on studies indicating modest short-term benefits. Yet, these earlier investigations lacked the granular, long-term follow-up and multimodal imaging assessments that contemporary cardiology research affords.

The multicenter trial led by Radboudumc enrolled 1,146 patients presenting with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease. Participants were randomized into two cohorts: those receiving non-culprit PCI during the acute phase alongside culprit lesion intervention, and those where the additional lesions were addressed only after a deliberate delay of up to six weeks. Over a follow-up period extending three years, clinical endpoints including mortality, recurrent myocardial infarction, and heart failure hospitalization were meticulously recorded.

Remarkably, the data demonstrated no statistically significant differences in primary outcomes between immediate and deferred treatment groups. The implications are profound, suggesting that allowing the patient to stabilize before undertaking additional PCI procedures does not expose them to increased risk. This insight advocates for a more measured and patient-specific approach, prioritizing the physiological stability and clinical context rather than reflexively aiming for expedited complete revascularization.

A critical element underpinning these findings relates to advancements in cardiac imaging strategies. During the acute episode, cardiologists assess vessel patency and ischemic burden through invasive pressure measurements with a pressure wire, estimating fractional flow reserve (FFR) to gauge the functional significance of stenoses. However, in the subacute phase, non-invasive modalities such as cardiac magnetic resonance imaging (MRI) offer a comprehensive appraisal of myocardial perfusion, tissue viability, and oxygenation status. This imaging capability enables clinicians to identify which lesions genuinely warrant stenting by revealing their actual impact on myocardial blood flow.

Professor Niels van Royen, a leading cardiologist involved in the study, emphasizes that stenting fewer vessels during the calmer follow-up phase results from this refined diagnostic approach. Many stenoses that appear critical under acute conditions do not impose substantial ischemic threat when the heart has stabilized and collateral circulation has developed. Consequently, indiscriminate immediate stenting risks overtreatment, exposing patients to procedural complications, prolonged intervention times, and unnecessary stent implantation.

Despite the evidence supporting deferred intervention, the researchers caution against deliberately postponing PCI unless clinically justified. Patient considerations such as fatigue, pain severity, or healthcare system logistics may render immediate full revascularization impractical. Importantly, the study provides reassurance that in such cases, pausing after addressing the culprit lesion remains a safe strategy, with follow-up assessment guiding further interventions selectively.

This paradigm shift encourages clinicians to engage patients in shared decision-making processes, highlighting the importance of follow-up adherence. A key takeaway is the pivotal role of returning for scheduled MRI scans weeks after the initial event, which can confirm myocardial oxygen sufficiency and obviate the need for additional stents in many cases. Nonetheless, patient noncompliance with follow-up remains an ongoing challenge that may limit the widespread adoption of this approach.

Looking ahead, the investigators anticipate that existing clinical practice guidelines will evolve to reflect these findings, moving away from blanket recommendations for immediate multivessel stenting. Such revisions would reconcile evidence gaps between earlier short-term benefit studies and the nuanced long-term data emerging from this comprehensive trial. The study exemplifies the critical importance of evidence-based medicine and personalized care tailored to individual patient physiology.

From a public health perspective, this research has significant implications. Halving the number of stent procedures reduces healthcare costs, potential complications, and resource utilization, all while maintaining therapeutic efficacy. Furthermore, by employing MRI assessments, clinicians harness sophisticated imaging technologies that exemplify precision medicine’s trajectory in cardiology.

In conclusion, this landmark study redefines the management of multivessel coronary artery disease in the context of acute heart attacks. The nuanced understanding gained affirms that quicker intervention is not invariably superior; instead, a strategy that balances urgency with physiological assessment maximizes patient safety and outcomes. As cardiology progresses toward integrating advanced imaging and individualized treatment timing, patients stand to benefit from therapies that are both scientifically sound and clinically prudent.

Subject of Research: People

Article Title: Immediate or Deferred Non-Culprit Vessel PCI in Myocardial Infarction

Web References: https://mediasvc.eurekalert.org/Api/v1/Multimedia/36222416-6649-483b-bf65-a00454649425/Rendition/low-res/Content/Public

References: New England Journal of Medicine

Image Credits: Radboudumc

Keywords: Myocardial infarction, Acute myocardial infarction, Multivessel coronary artery disease, Percutaneous coronary intervention, Cardiac MRI, Fractional flow reserve, Stent procedure, Cardiovascular research

Platelets, tiny but vital components in blood, act as first responders during vascular injury, aggregating rapidly to seal wounds and prevent excessive bleeding. However, in individuals with CAD, these platelets may go into overdrive, creating hazardous clots that block arterial blood flow, ultimately heightening the risk of heart attacks and strokes. Despite the importance of controlling platelet activity with antiplatelet drugs, doctors have long faced challenges in accurately measuring the effectiveness of these treatments on a patient-by-patient basis. This uncertainty leaves critical gaps in optimizing therapeutic interventions.

To tackle this issue, Dr. Kazutoshi Hirose and his team developed an innovative system that captures platelets in action with remarkable clarity and speed. At the heart of this innovation is an FDM microscope—a sophisticated optical device capable of taking thousands of high-resolution images of blood cells flowing through vessels every second. Unlike traditional microscopes, this technology moves beyond static imaging, effectively acting as a high-speed camera filming the dynamic interactions of cells in real-time.

Once the FDM microscope generates these rapid-fire images, the research team employs AI algorithms specifically trained to distinguish between individual blood components in motion. The AI is adept at recognizing solitary platelets, clusters of platelets, and even white blood cells, which can sometimes interact with or influence clot formation. This level of precise categorization is crucial, as the formation and size of platelet aggregates directly correlate with clotting risk and the severity of CAD symptoms.

The research, involving over 200 patients, revealed significant differences in platelet aggregation between those suffering from acute coronary syndrome and patients with more stable, chronic conditions. Acute patients exhibited markedly larger platelet clumps, a finding that aligns with heightened clotting risk and supports the technology’s potential as a predictive diagnostic tool. These insights underscore the capacity of this system to provide real-time clotting risk assessments, potentially enabling doctors to intervene more swiftly and with greater precision.

One of the most remarkable breakthroughs of the study is the discovery that simple venous blood draws from the arm deliver nearly the same valuable platelet activity information as blood sampled invasively from coronary arteries. Conventional methods require catheter insertion, a procedure that can be uncomfortable, risky, and resource-intensive. This less invasive approach promises to simplify monitoring protocols, lower patient risk, and broaden access to platelet activity testing in diverse clinical settings.

Dr. Hirose emphasized the clinical significance of these findings, highlighting that tailored therapy adjustments based on real-time platelet behavior could minimize both ischemic events caused by clots and bleeding complications associated with over-medication. This personalization aligns with the growing movement in medicine toward precision treatment, where therapies are fine-tuned according to individual patient profiles rather than a one-size-fits-all approach.

The underlying AI technology is a pivotal aspect of this research, offering capabilities far beyond human visual perception. AI’s ability to detect subtle patterns and fluctuations in platelet behavior within seconds makes it an invaluable partner in clinical diagnosis and drug efficacy evaluation. This harnessing of machine learning in biomedical imaging exemplifies the fusion of computational power and medical innovation, a trend likely to accelerate across many fields of healthcare.

Co-author Yuqi Zhou illustrated how the system mirrors traffic monitoring techniques, where a camera not only counts individual cars but also identifies traffic jams and emergency vehicles. In the bloodstream, single platelets are akin to individual cars, platelet clumps resemble traffic jams, and white blood cells are like police cars that can influence the scene. Such analogies help conceptualize the complexity and high-resolution detection capacity of the technology.

Professor Keisuke Goda, the project’s lead, reflected on the transformative potential of combining high-speed optical imaging with AI, stressing how these advances allow unprecedented observation of blood cells in their natural flowing state. This approach shatters previous limitations of static slide samples or indirect testing, opening new avenues for real-time blood analysis and cardiovascular risk assessment.

Beyond CAD, the implications for this technology could extend to other disorders involving abnormal blood clotting, including stroke, deep vein thrombosis, and certain inflammatory diseases. By providing a window into the microscopic blood traffic with fine detail and speed, this FDM microscope and AI system might redefine both diagnostics and the monitoring of therapeutic responses in various hematologic conditions.

Looking forward, the researchers aim to integrate this technology into clinical workflows, enabling more frequent and less invasive monitoring of at-risk patients. The ultimate vision is a new standard of care where personalized antiplatelet treatments are dynamically adjusted based on continuous or periodic direct observation of platelet behavior, enhancing both safety and efficacy.

This study, published in Nature Communications, underscores the power of interdisciplinary collaboration—melding optics, machine learning, and clinical medicine—to address longstanding challenges in cardiovascular health. It stands as a compelling example of how emergent technologies can reveal hidden physiological stories that ultimately improve patient outcomes and save lives.

Subject of Research: Human tissue samples
Article Title: Direct evaluation of antiplatelet therapy in coronary artery disease by comprehensive image-based profiling of circulating platelets
News Publication Date: 15-May-2025
Web References: http://dx.doi.org/10.1038/s41467-025-59664-8
References: Kazutoshi Hirose et al., Nature Communications, 2025
Image Credits: ©2025 Hirose et al CC-BY-ND
Keywords: platelet aggregation, coronary artery disease, FDM microscope, artificial intelligence, antiplatelet therapy, high-speed imaging, blood clotting, cardiovascular risk, non-invasive diagnostics, real-time monitoring

Zhao’s research centers on developing innovative technology that evaluates Fractional Flow Reserve (FFR), a crucial measurement in diagnosing coronary artery disease (CAD). CAD stands as the leading cause of mortality in the United States, with the Centers for Disease Control and Prevention reporting between 375,000 to 400,000 deaths annually due to this condition. The statistics underline an urgent need for improved diagnostic methods, which is precisely the gap Zhao aims to bridge through his work.

Historically, traditional FFR measurement techniques involve invasive procedures that can be both time-intensive and costly. They often depend on computational fluid dynamics methods that may take hours to yield results. Zhao’s innovative approach intends to create a non-invasive method for evaluating FFR that dramatically shortens the evaluation time to mere seconds. This breakthrough could not only enhance the speed of diagnoses but also lessen the associated risks for patients undergoing cardiovascular evaluations.

The technology being developed by Zhao capitalizes on coronary computed tomography angiography (CCTA) scans to assess FFR. Traditional techniques involve threading a wire into the arteries to analyze pressure differentials and thereby diagnose blockages, a method fraught with risks and discomfort for the patient. By shifting to a non-invasive technique, Zhao is redefining how diagnoses can be performed, aiming ultimately for an approach that maximizes patient comfort while optimizing accuracy.

Zhao articulated the transformative potential of his research, stating that it is not merely an improvement to an existing diagnostic method but an overhaul of the entire cardiovascular diagnostic workflow. Real-time results, he suggests, could empower healthcare providers to make quicker, more informed decisions regarding patient care. This immediacy could be life-saving, emphasizing the real-world implications of his research efforts.

The accolades for Zhao’s work extend beyond its technical prowess, with Sumanth Yenduri, the Dean of the College of Computing and Software Engineering at Kennesaw State University, commending his contributions. Yenduri emphasized that Zhao’s research exemplifies the transformative capacity of interdisciplinary work, effectively merging the realms of computer science with healthcare in a way that highlights significant societal impacts.

Zhao’s fascination with cardiovascular research initiated during his doctoral studies, during which he first engaged with advanced cardiovascular imaging techniques. This early exposure ignited a desire to harness computer science in the realm of medical imaging, with the ultimate aim of refining and improving diagnostic processes. The idea to utilize CCTA for FFR prediction stemmed from a commitment to eliminating the risks associated with invasive methodologies.

The conventional approach to FFR prediction, despite its widespread use, involves significant complications. CCTA scans capture images of the coronary arteries but calculating FFR from these images using traditional computational flow dynamics methods requires extensive time and resources. Zhao recognized the potential for leveraging deep learning combined with physics-informed neural networks to revolutionize this tedious process, aiming to produce both accuracy and efficiency.

In addition to addressing current diagnostic challenges, Zhao’s vision encompasses a broader horizon. He hopes to explore the untapped potential of artificial intelligence within the realm of medical diagnostics. By refining the technologies at his disposal, he aims not only to enhance the process of diagnosing heart disease but also to potentially expand his methodologies to other medical fields.

The ultimate goal of Zhao’s research is the improvement of patient outcomes and quality of life on a global scale. He envisions a future where breakthroughs in medical imaging are commonplace, offering unprecedented advancements in diagnostics that could alter the landscape of patient care. This ambition drives his ongoing research, propelling him forward into uncharted territories of medical and technological innovation.

Zhao’s journey highlights the importance of interdisciplinary collaboration in driving meaningful advancements in health care solutions. As the fields of computer science and healthcare continue to converge, the implications of such research could pave new pathways to understanding and treating a multitude of conditions that afflict populations worldwide.

As technology continues to evolve, Zhao’s work stands at the forefront of transformative medical research. Not only is he developing methodologies and technologies that could redefine patient diagnostics, but he is also contributing to a broader narrative about the convergence of technology and medicine, hoping to inspire the next generation of researchers to explore these vital intersections.

The future of cardiovascular diagnostics may very well hinge on innovations like those being introduced by Chen Zhao. As he continues to push the boundaries of what is achievable in medical imaging, the potential benefits for countless patients around the world remain at the core of his objectives, driving his research forward with both rigor and compassion.

—

Subject of Research: Non-invasive blood flow prediction in cardiovascular disease diagnostics
Article Title: Kennesaw State University’s Chen Zhao Receives 2025 AHA Award for Groundbreaking Cardiovascular Research
News Publication Date: October 2023
Web References: N/A
References: N/A
Image Credits: Darnell Wilburn / Kennesaw State University

Keywords: Cardiovascular disease, Coronary artery disease, Blood flow, Medical imaging, AI in healthcare, Research enhancement, Non-invasive diagnosis, Health technology.